Pharmacology

Grenoble. Brenneman KA, Wong BA, Buccellato MA, Costa ER, Gross EA, Dorman DG, 2000. Direct olfactory transport of inhaled manganese (54MnCl2) to the rat brain: toxicokinetic investigations in a unilateral nasal occlusion model. Toxicology and Applied Pharmacology 169 : 238-248. British Standards Institute (BSI), 2008. Nanotechnologies – Part 2: Guide to safe handling and disposal of manufactured nanomaterials. PD 6699-2 : 2007, BSI, London. Brouwer DH, Gijsbers JHJ, Lurvink MWM, 2004. Personal Exposure

Scientist 166, 15. Chirac P, von Schoen-Angerer T, Kasper T & Ford N (2000) AIDS: patent rights versus patient's rights. Lancet 356, 502. DiMasi J, Seibring MA & Lasagna L (1994) New drug developments in the United States from 1963 to 1992. Clinical Pharmacology and Therapeutics 55, 609±622. Donald A (1999) Political economy of technology transfer. British Medical Journal 319, 1298±1299. Fortune 500 (2001) Top Performing Industries. http://www. fortune500.com. Gambardella A, Orsenigo L & Pammolli F (2001)

dilation of large coronary arteries in conscious dogs. Circulation 1995;92:2627-2635 [7] Lockhandwala MF, Barrett RJ. Dopamine receptor agonists in cardiovascular therapy. Drug Res 1983;3:299-310 [8] Prys-Roberts C. The changing face of adrenergic pharmacology. Current Opinion in Anaesthesiology 1992;5:113-124 [9] Cohn JN, Levine TB, Olivari MT, Garbert V, Lura D, Francis GS, Simon AB, Victor T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J

It is this construction of a technical system that combines different functionalities which bring liposomes, polymer-protein conjugates, dendrimers, and other nanoparticles into the realm of nanotechnology proper, as opposed to traditional pharmacology or supramolecular chemistry.13 Also, it is this modularity which answers nanomedicine's call for "design on a disease-specific basis." While EU and US reports on nanomedicine emphasise the notion of design, the European Technology Platform

administration does not result in a physical dependence syndrome. Tobacco Resolution, Bates Number 1000060695-60704 44 Les additifs du tabac 44. Philip Morris, 1983 Victor J DeNoble ‘Behavioral Pharmacology annual report’. Tobacco Resolution, Bates Number 20605661145. Philip Morris 1983, «Behavioural Pharmacology Annual Report» V. J. DeNoble. Tobacco Resolution, BN 206056611-6612 46. Philip Morris 1982, Evaluation of the DeNoble nicotine acetaldehyde Data, Tobacco Resolution, BN 2056144727-4728. 47.

métallothioneines chez deux modioles hydrothermales: Bathymodiolus thermophiles et Bathymodiolus azoricus. Thèse de Doctorat de l’université de Maine UFR Sciences et Techniques, 164p. • Kakkar P., Jaffery F.N., 2005. Environmental. Toxicology and Pharmacology 19, 335-349. • Miquel G., 2001. Les effets des métaux lourds sur l'environnement et la santé. Rapport Office Parlementaire d'évaluation des choix scientifiques et technologiques (Dir.). Rapport Sénat n°261: 360. • Nakib Lydia 2010

Journal of Psychiatry, 158:2015--2021. 14. Volkow ND et al. (2001b) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. American Journal of Psychiatry, 158:377--382. 15. Kalant H (2001) The pharmacology and toxicology of ‘‘ecstasy’’ (MDMA) and related drugs. Canadian Medical Association Journal, 165:917--928. 16. Montoya AG et al. (2002) Long-term neuropsychiatric consequences of ‘‘ecstasy’’ (MDMA): a review. Harvard Review of Psychiatry, 10:212--220

Beta-endorphin and drug-induced reward and reinforcement. Prog Neurobiol. 2008; 86:1–21. [PubMed: 18602444] 28. Roques BP, Noble F, Daugé V, Fournié-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev. 1993; 45:87– 146. [PubMed: 8475170] 29. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature. 1995; 377:532–35

prevalence of obesity in Western Samoa over the 13 year period 1978–1991. International Journal of Obesity and Related Metabolic Disorders, 1994, 18:419–428. 74. Gracey M. New World syndrome in Western Australian aborigines. Clinical and Experimental Pharmacology and Physiology, 1995, 22:220–225. 164 75. Raikes P. Modernising hunger: famine, food surplus and farm policy in the EEC and Africa. Londres (Royaume-Uni), Catholic Institute for International Relations/James Currey, 1988. 76. Drenowski A,

support papier, les meilleurs ouvrages généraux sont en langue anglaise : • GOODMAN & GILMAN’S. The pharmacological basis of therapeutics. McGrawHill, 10e édition, 2003 Le plus complet, mais pour travail approfondi, • RANG HP, DALE MM, RITTER JM. Pharmacology. Churchill Livingstone, 5e édition, 2000 Le plus didactique. La version électronique du cours de pharmacologie médicale de Bordeaux est consultable sur le site du département de pharmacologie : www.pharmacologie.u-bordeaux2.fr N.B. : les